Dana Pizzuti insider trades: Crinetics Pharmaceuticals (CRNX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Dana reports to the SEC
Open-market buys and sales
17 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 1, 2025 | CRNX | ↓ Sell | 5,000 | $45.02 | $225K | Direct | Dec 3, 2025 (2d) |
| Nov 3, 2025 | CRNX | ↓ Sell | 5,000 | $42.66 | $213K | Direct | Nov 5, 2025 (2d) |
| Oct 1, 2025 | CRNX | ↓ Sell | 5,000 | $41.81 | $209K | Direct | Oct 3, 2025 (2d) |
| Sep 2, 2025 | CRNX | ↓ Sell | 5,000 | $32.10 | $161K | Direct | Sep 4, 2025 (2d) |
| Aug 22, 2025 | CRNX | ↓ Sell | 30,000 | $30.43 | $913K | Direct | Aug 26, 2025 (4d) |
| Aug 20, 2025 | CRNX | ↓ Sell | 6,492 | $29.18 | $189K | Direct | Aug 21, 2025 (1d) |
| Mar 19, 2025 | CRNX | ↓ Sell | 2,515 | $34.20 | $86K | Direct | Mar 21, 2025 (2d) |
| Feb 3, 2025 | CRNX | ↓ Sell | 5,000 | $39.07 | $195K | Direct | Feb 5, 2025 (2d) |
| Jan 3, 2025 | CRNX | ↓ Sell | 15,000 | $52.09 | $781K | Direct | Jan 7, 2025 (4d) |
| Oct 3, 2024 | CRNX | ↓ Sell | 14,375 | $54.63 | $785K | Direct | Oct 7, 2024 (4d) |
| Jul 3, 2024 | CRNX | ↓ Sell | 14,375 | $44.87 | $645K | Direct | Jul 5, 2024 (2d) |
| Jun 24, 2024 | CRNX | ↓ Sell | 9,500 | $45.73 | $434K | Direct | Jun 25, 2024 (1d) |
| Apr 15, 2024 | CRNX | ↓ Sell | 14,375 | $44.47 | $639K | Direct | Apr 17, 2024 (2d) |
| Mar 20, 2024 | CRNX | ↓ Sell | 15,089 | $44.06 | $665K | Direct | Mar 22, 2024 (2d) |
| Jan 3, 2024 | CRNX | ↓ Sell | 14,375 | $35.00 | $503K | Direct | Jan 4, 2024 (1d) |
| Dec 21, 2023 | CRNX | ↓ Sell | 9,583 | $34.57 | $331K | Direct | Dec 22, 2023 (1d) |
| Apr 5, 2023 | CRNX | ↓ Sell | 8,212 | $16.15 | $133K | Direct | Apr 5, 2023 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other CRNX insiders
Open-market trades in the last 12 months
About Dana Pizzuti's insider trades
Dana Pizzuti is Chief Med and Dev Officer at Crinetics Pharmaceuticals (CRNX). Since Apr 5, 2023, Dana has reported no open-market purchases and 17 sales worth $7.1M on SEC Form 4. In the last 12 months: 1 sale ($225K).
Their filings also include option exercises (14 filings), grants and awards (4 filings), shares withheld for taxes (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CRNX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.